Applied Research Systems Ars Holding N.v.

Laboratoires Serono S.a.

Ruben Papoian

Ursula Boschert

Georg Feger

Lilia Bernasconi

Raghuram Selvaraju

Mauro Biffoni

The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.

Use of osteopontin for the treatment and/or prevention of neurologic diseases

A method to prevent graft rejection of transplanted cells, tissues or organs without general immunosuppression is described. The method employs a newly discovered protein, LAG-3. When allogeneic or xenogeneic cells are engineered to express LAG-3 on their surface and transplanted, immune destruction of the implanted cell, tissue or organ is prevented, while the host's immune system remains functional. A particular application of this method allows the preparation of a universal gene therapy host cell expressing LAG-3 on its surface for protection from graft rejection by a host's immune system.

Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)

Growing community of inventors

Cincinnati, OH, United States of America

Ruben Papoian